AngioDynamics is expected to report its fiscal fourth-quarter 2026 earnings results shortly. The medical device manufacturer’s financial performance is a key gauge for investor sentiment in the interventional oncology and vascular access device sectors. SeekingAlpha reported on July 13, 2026, that the company’s preliminary guidance projects quarterly revenue of approximately $87 million. This figure represents a critical baseline for assessing the firm's recovery trajectory and operational execution following recent macroeconomic and sector-specific pressures.
Context — why this matters now
The fiscal Q4 2026 report follows a period of significant volatility for small-to-mid-cap medical device firms. Regulatory scrutiny from the U.S. Food and Drug Administration has intensified for class II and III devices. Supply chain disruptions that plagued the sector in 2024 and 2025 have largely normalized, but input cost inflation for specialized polymers and electronic components persists at a 3-5% annual rate.
AngioDynamics is in the midst of a multi-year portfolio transformation. The company divested its NAMIC fluid management business in late 2025 for $240 million. Proceeds were earmarked for debt reduction and to bolster commercial efforts for higher-growth platforms like the Auryon atherectomy system and AlphaVac mechanical thrombectomy device. The upcoming earnings call will provide concrete data on the commercial uptake of these flagship products.
Investor focus has shifted from top-line growth to sustainable profitability. The last major medical device firm to miss both revenue and earnings guidance in a similar product segment, Penumbra in Q3 2025, saw its stock decline 22% in the subsequent trading session. This establishes a clear precedent for market punishment on execution missteps.
Data — what the numbers show
The company's projected Q4 revenue of $87 million compares to prior year Q4 revenue of $83.5 million, indicating a potential year-over-year growth rate of 4.2%. Wall Street consensus analyst estimates for adjusted earnings per share cluster around $0.08 for the quarter. The firm’s gross margin target remains in the 53-55% range, a benchmark it has struggled to consistently achieve.
A key metric will be procedure volume growth for its thrombectomy and atherectomy systems. Procedure growth in fiscal Q3 2026 was reported at 12% year-over-year. Sustaining double-digit growth is critical for justifying the company's current valuation. The broader iShares U.S. Medical Devices ETF (IHI) has returned -2.3% year-to-date, underperforming the S&P 500's +8.1% gain.
AngioDynamics' balance sheet shows a cash position of roughly $45 million as of the end of Q3 2026, with total debt of approximately $180 million. The net debt-to-EBITDA ratio, a measure of use, stood at 3.2x. Management has stated a goal to reduce this ratio below 2.5x by the end of fiscal 2027.
Product Segment | Q3 2026 Revenue | Growth Driver
---------------|-----------------|--------------
Vascular Access | $42M | Stable, low single-digit growth
Interventional Oncology & Peripheral Vascular | $38M | Auryon & AlphaVac adoption
Analysis — what it means for markets / sectors / tickers
A revenue beat above $89 million would likely provide a positive catalyst for AngioDynamics shares and could lift peers in the niche interventional device space. Direct beneficiaries could include smaller-cap firms like Surmodics (SRDX) and Shockwave Medical (SWAV), which trade on similar growth narratives. A miss below $85 million may trigger a sector re-rating, increasing pressure on firms like Inari Medical (NARI) to demonstrate insulated demand.
The primary counter-argument is that procedure growth may not translate to proportional revenue growth due to pricing pressure. Medicare reimbursement rates for certain thrombectomy codes were cut by 4% in the 2026 physician fee schedule. Hospitals and ambulatory surgical centers are aggressively negotiating device pricing, potentially compressing manufacturer margins despite higher unit volumes.
Positioning data from the prior quarter shows hedge funds increased their short interest in ANGO by 15%. This suggests a segment of sophisticated investors is betting against a successful turnaround. Flow data indicates institutional buyers have been net sellers over the past three months, with selling pressure intensifying on days when the broader healthcare sector underperforms.
Outlook — what to watch next
Immediate catalysts include the official earnings release date, expected within two weeks of the July 13 preview. The accompanying conference call will provide management commentary on forward guidance for fiscal 2027. Investors will scrutinize any update on the timeline for full commercial launch of next-generation AlphaVac iterations.
Key technical levels for ANGO stock include support at $9.50, which held during the market sell-off in May 2026, and resistance at $12.80, the 200-day moving average. A sustained break above the 200-day MA on high volume would signal a potential trend reversal.
The next major industry event is the Cardiovascular Research Technologies (CRT) conference in late February 2027, where clinical data updates for competing devices are typically presented. Regulatory decisions from the FDA on pending 510(k) clearances for peripheral vascular devices are a constant pipeline monitor for the sector.
Frequently Asked Questions
What does AngioDynamics do?
AngioDynamics designs, manufactures, and sells medical devices used by interventional radiologists, cardiologists, and surgeons. Its core products are minimally invasive devices for treating peripheral vascular disease and removing blood clots. Key platforms include the Auryon laser atherectomy system, which ablates plaque in arteries, and the AlphaVac mechanical thrombectomy system, which is designed for the emergency removal of large blood clots.
How does AngioDynamics' valuation compare to its peers?
AngioDynamics trades at a significant discount to its peer group on a sales multiple basis. As of July 2026, ANGO trades at an enterprise-value-to-sales multiple of approximately 1.5x. In contrast, faster-growing peers like Inari Medical trade above 8x sales, and larger, more diversified firms like Boston Scientific trade around 4.5x sales. This discount reflects the market's skepticism about ANGO's ability to return to consistent profitability and gain meaningful market share.
What are the biggest risks facing AngioDynamics?
The two largest risks are reimbursement and competition. Government and private insurers periodically review and can reduce payment rates for medical procedures, directly impacting hospital budgets for device purchases. Secondly, the peripheral vascular and thrombectomy markets are intensely competitive, featuring larger, better-capitalized rivals like Boston Scientific, Medtronic, and Philips, who can invest more heavily in R&D and sales force expansion, potentially crowding out smaller players.
Bottom Line
AngioDynamics' Q4 revenue projection sets a tangible benchmark for its ongoing portfolio transition and commercial execution.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.
